Company: SUPN
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001104659-25-042531
Chunk: 48

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 48
---
 or a portion of the risk of a decline in the market price of shares of our common stock. Our Insider Trading Policy also prohibits directors, CEO, other NEOs as well as all other employees from pledging our securities or holding such securities in a margin account. For additional details regarding our Insider Trading Policy and the other restrictions it contains see “Corporate Governance — Insider Trading Policy”. Policy Against Repricing Stock Options The Company has a consistent policy against the repricing of stock options without stockholder approval. Award Forfeiture Upon Termination for Cause An executive may be terminated for cause, due to dishonesty, embezzlement, theft or fraudulent misconduct or for other reasons. In such a case, any unpaid and/or unvested incentive awards as of the date of termination would be forfeited. Benefits in Connection with Termination of Employment Certain of our executives have agreements related to payments upon a change of control of the Company, which agreements are discussed below under the heading “Executive Compensation — Employment Agreement, Offer Letter and Severance Benefits” of this Proxy Statement. 31 REPORT OF THE COMPENSATION COMMITTEE The information contained in this report shall not be deemed to be “soliciting material” or “filed” or incorporated by reference in future filings with the SEC, or subject to the liabilities of Section 18 of the Exchange Act, except to the extent that the Company specifically incorporates it by reference into a document filed under the Securities Act or the Exchange Act. The Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K with management and, based on such review and discussions, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this Proxy Statement and incorporated by reference into the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. Compensation Committee: Georges Gemayel, Ph.D. (Chair),
Frederick M. Hudson,
Charles W. Newhall, III 32

EXECUTIVE COMPENSATION Summary Compensation Table The following table shows the compensation earned by our CEO and other NEOs during the fiscal years ended December 31, 2023, December 31, 2022 and December 31, 2021.

| Name and Principal Position                                                                              | ​ | ​ | Year |   |      |   | ​ | ​ | Salary($) |   |           |   | ​ | ​ | StockAwards($)(1) |   |           |   |